您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Clarithromycin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Clarithromycin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Clarithromycin图片
CAS NO:81103-11-9
规格:98%
分子量:747.95
包装与价格:
包装价格(元)
100mg电议
200mg电议

产品介绍
CYP3A inhibitor, potent
CAS:81103-11-9
分子式:C38H69NO13
分子量:747.95
纯度:98%
存储:Store at -20°C

Background:

Clarithromycin, is a potent inhibitor of the cytochrome P450 isoenzyme CYP3A, might build the plasma concentration of statins metabolized by this pathway; therefore, increase the risk of interaction with statins in reference to pharmacokinetic studies.


Among 28,484 medicines of clarithromycin, 2317 persons were co-presented to statins. Co-organization of CYP3A4 metabolized statins and clarithromycin was connected with a 2.11 fold expanded danger of death or hospitalization (95 % certainty interim [CI]: 1.79-2.48). This impact was clarified by age, proof of cardiovascular malady, diabetes mellitus and use of different anti-infection agents (multivariable balanced danger proportion: 1.02, 95 % CI: 0.85-1.22). The affectability examinations did not change the noteworthiness of effect.


The danger for hospitalization or passing in persons accepting clarithromycin increments with age and cardiovascular disease yet is not causally connected with statin-clarithromycine co-organization.


Reference:
A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.  Lipids Health Dis. 2015 Oct 24;14:131.